selected scholarly activity
-
chapters
-
conferences
- Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.. Journal of Clinical Oncology. 659-659. 2022
- EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology. 2004-2004. 2021
- 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1). Annals of Oncology. S708-S709. 2020
- Evaluating the impact of COVID-19 on medical oncology workforce and cancer care in Canada: A serial survey study.. Clinical Cancer Research. 2020
- FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Annals of Oncology. 2019
- Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE. Cancer immunology research. B207-B207. 2019
- Assessment of myocardial injury early after initiation of treatment in breast cancer patients using the Beckman Coulter and Abbott Diagnostics high-sensitivity cardiac troponin I tests. Clinical Biochemistry. 56-57. 2018
- Abstract 2556: Expanded ovarian cancer patient NK cells represent a novel, cytotoxic phenotype and reduce autologous tumor in a patient-derived xenograft ovarian cancer model. Cancer Research. 2556-2556. 2018
- EFFECTS OF ITRACONAZOLE ON THE PHARMACOKINETICS OF COPANLISIB, A NOVEL PAN-CLASS I PHOSPHATIDYLINOSITOL-3-KINASE INHIBITOR IN CANCER SUBJECTS.. Clinical Pharmacology and Therapeutics. S86-S86. 2018
- PATTERNS OF TTFIELDS-RELATED SEVERE SKIN TOXICITY IN GBM PATIENTS. Neuro-Oncology. 3-3. 2017
- TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 138-138. 2017
- Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia.. Journal of Clinical Oncology. 5587-5587. 2017
- Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.. Journal of Clinical Oncology. 5506-5506. 2017
- Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.. Journal of Clinical Oncology. 5524-5524. 2017
- Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221. European Journal of Cancer. S97-S98. 2016
- ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 17-18. 2016
- ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 17-17. 2016
- A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI). Annals of Oncology. vi167-vi167. 2016
- A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. Journal of Clinical Oncology. LBA2-LBA2. 2016
- Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. Journal of Clinical Oncology. 5547-5547. 2016
- Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. Journal of Clinical Oncology. 5586-5586. 2016
- A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 2541-2541. 2015
- A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology. 3061-3061. 2015
- NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology. 2594-2594. 2015
- Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial.. Journal of Clinical Oncology. 2000-2000. 2015
- 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041). European Journal of Cancer. 165-166. 2014
- Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting. International Journal of Radiation Oncology Biology Physics. S908-S908. 2014
- A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology. TPS5631-TPS5631. 2014
- A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.. Journal of Clinical Oncology. 5519-5519. 2014
- Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. Journal of Clinical Oncology. 2535-2535. 2014
- Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.. Journal of Clinical Oncology. TPS5629-TPS5629. 2014
- Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.. Journal of Clinical Oncology. TPS5620-TPS5620. 2014
- RANDOMISED DOUBLE-BLIND PHASE III TRIAL OF CEDIRANIB (AZD 2171) IN RELAPSED PLATINUM SENSITIVE OVARIAN CANCER: RESULTS OF THE ICON6 TRIAL.. International Journal of Gynecological Cancer. 2013
- Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European Journal of Cancer. S5-S6. 2013
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. Journal of Clinical Oncology. 2013
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.. Journal of Clinical Oncology. 2542-2542. 2013
- A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia. Journal of Clinical Oncology. 2013
- A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.. Journal of Clinical Oncology. 2013
- A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.. Journal of Clinical Oncology. 2523-2523. 2013
- Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.. Journal of Clinical Oncology. 2013
- Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041). Journal of Clinical Oncology. 2013
- Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program. Journal of Clinical Oncology. 2013
- A PHASE I STUDY OF THE COMBINATION OF RO4929097 (RO) AND CEDIRANIB (CD) IN PATIENTS WITH ADVANCED SOLID TUMORS (PJC-004/NCI 8503). Annals of Oncology. 155-156. 2012
- A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. Annals of Oncology. 156-156. 2012
- A Phase I Study of the Combination of RO4929097 (RO) And Cediranib (CD) in Patients with Advanced Solid Tumors (PJC-004/NCI 8503). Annals of Oncology. ix155-ix156. 2012
- A Phase IB Combination Study of RO4929097 (RO), A Gamma-Secretase Inhibitor, and Temsirolimus (TEM) in Patients (PTS) with Advanced Solid Tumors. Annals of Oncology. ix156-ix156. 2012
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology. 2012
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. Journal of Clinical Oncology. 3082-3082. 2012
- A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia. Journal of Clinical Oncology. 2012
- Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology. 2012
- Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.. Journal of Clinical Oncology. 2012
- Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.. Journal of Clinical Oncology. e13011-e13011. 2012
- Abstract C17: A phase I study of the combination of RO4929097 (RO) and cediranib (Cd) in patients with advanced solid tumors (PJC-004/NCI 8503).. Molecular Cancer Therapeutics. C17-C17. 2011
- Fractionated Stereotactic Radiosurgery with Concurrent Temozolomide for Locally Recurrent Glioblastoma Multiforme: A Prospective Study. International Journal of Radiation Oncology Biology Physics. S281-S281. 2011
- NT-proBNP measurement using a multiplex platform in cancer and chest pain populations. Clinical Biochemistry. 1172-1172. 2011
- A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3099-3099. 2011
- The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5.. Journal of Clinical Oncology. 5088-5088. 2011
- 491 NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly. European Journal of Cancer, Supplement. 157-157. 2010
- Early changes in biomarkers determined by LC/MS/MS and ELISA based methods in a phase I/II study assessing an anti-metastatic agent. Clinical Biochemistry. 781-782. 2010
- A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. Journal of Clinical Oncology. 2010
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.. Journal of Clinical Oncology. 3002-3002. 2010
- Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 5002-5002. 2010
- Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.. Journal of Clinical Oncology. 3077-3077. 2010
- Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. Molecular Cancer Therapeutics. A185-A185. 2009
- Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors. Molecular Cancer Therapeutics. B54-B54. 2009
- P71 Vascular endothelial growth factor (VEGF) inhibition and erythropoiesis – a missing link?. European Journal of Cancer, Supplement. 36-36. 2009
- 163 OUTCOMES AND PREDICTORS OF SURVIVAL FOLLOWING CONCOMITANT AND ADJUVANT TEMOZOLOMIDE WITH RADIOTHERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME. Radiotherapy and Oncology. S52-S52. 2009
- A mass spectrometry approach to identify surrogate biomarkers; for early responders to an anti-metastatic/anti-tumor investigational agent. Clinical Chemistry. A114-A115. 2009
- Cytokines and cell adhesion molecules exhibit cancer specific profiles in patients with metastatic disease treated with an investigational anti-metastatic agent. Clinical Chemistry. A116-A117. 2009
- A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Journal of Clinical Oncology. 2009
- A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 2009
- OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. Journal of Clinical Oncology. 2009
- OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. Journal of Clinical Oncology. 3506-3506. 2009
- Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. Journal of Clinical Oncology. 2009
- 112 POSTER A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis. European Journal of Cancer, Supplement. 37-37. 2008
- 206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC). European Journal of Cancer, Supplement. 65-65. 2008
- 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. European Journal of Cancer, Supplement. 127-127. 2008
- Pilot study assessing the utility of an adhesion array and high-sensitivity cytokine array as surrogate biomarkers in ovarian cancer. Clinical Biochemistry. 1271-1271. 2008
- A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. Journal of Clinical Oncology. 5521-5521. 2008
- A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. Journal of Clinical Oncology. 5582-5582. 2008
- A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. Journal of Clinical Oncology. 5518-5518. 2008
- A phase 2 trial of SNS-595 in women with platinum-refractory epithelial ovarian cancer. Gynecologic Oncology. S128-S128. 2008
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. Journal of Clinical Oncology. 76-82. 2008
- A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Molecular Cancer Therapeutics. 3371S-3371S. 2007
- Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Molecular Cancer Therapeutics. 3385S-3386S. 2007
- SNS-595 demonstrates initial clinical activity in a phase 2 trial in platinum resistant epithelial ovarian cancer. Molecular Cancer Therapeutics. 3387S-3388S. 2007
- A phase 1 study of the selective cyclin dependent kinase inhibitor P276–00 in patients with advanced refractory neoplasms. Journal of Clinical Oncology. 14117-14117. 2007
- 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors. European Journal of Cancer, Supplement. 167-167. 2006
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer. 1148-1154. 2006
- Ontario tumour bank initiative at Hamilton Health Sciences and the Juravinski Cancer Centre. Modern Pathology. 52-52. 2006
- Angiagenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial.. Journal of Clinical Oncology. 260S-260S. 2006
- Dose banding of chemotherapy doses at the Juravinski Cancer Centre.. Journal of Clinical Oncology. 325S-325S. 2006
- HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Clinical Cancer Research. 9104S-9104S. 2005
- A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. Journal of Clinical Oncology. 3085-3085. 2005
- A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial. Journal of Clinical Oncology. 223S-223S. 2005
- A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium.. Journal of Clinical Oncology. 349S-349S. 2005
- HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. Journal of Clinical Oncology. 3052-3052. 2005
- HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Journal of Clinical Oncology. 204S-204S. 2005
- Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial.. Journal of Clinical Oncology. 455S-455S. 2005
- 208 HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial. European Journal of Cancer, Supplement. 64-64. 2004
- A phase 2, single agent study of Cl-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.. Journal of Clinical Oncology. 462S-462S. 2004
- Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA).: Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCICCTG and the EORTC GCG.. Journal of Clinical Oncology. 450S-450S. 2004
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 171S-171S. 2004
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 2533-2533. 2004
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 2533-2533. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 204S-204S. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 3037-3037. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 3037-3037. 2004
- Phase II study of topotecan (T) in combination with the novel kinase inhibitor ucUCN-01 in patients with advanced cancer.. Clinical Cancer Research. 6223S-6223S. 2003
- Phase I study to determine the safety and pharmacokinetics of BAY 43-9006 in patients with advanced refractory solid tumors.. Clinical Cancer Research. 3768S-3768S. 2001
- NCICCTG OV12: An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel plus platinum containing chemotherapy (CT).. Annals of Oncology. 144-144. 2000
- BAY 12-9566, a selective, non-peptidic biphenyl inhibitor of matrix metalloproteases (MMPs): summary of phase I clinical and pharmacokinetic (PK) results.. Clinical Cancer Research. 3731S-3731S. 1999
- Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients (pts) with solid tumors - an NCIC Clinical Trials Group study.. Clinical Cancer Research. 3794S-3794S. 1999
- NCIC CTG IND 113: two phase I dose escalation pharmacokinetic (PK) studies of BAY 12-9566 (BAY) in combination with either doxorubicin (DOX) or modulated 5-fluorouracil (FU). European Journal of Cancer. S283-S283. 1999
- Clinical and pharmacokinetic (PK) results of 4 phase I studies of the second generation matrix metalloprotease (MMP) inhibitor Bay 12-9566, a non-peptidic biphenyl inhibitor of MMPs 2, 3&9. Annals of Oncology. 125-125. 1998
- Phase I study of the matrix metalloprotease inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer. Annals of Oncology. 75-75. 1998
- Planned and completed NCIC CTG trials with BAY 12-9566, a novel metalloprotease inhibitor (MMPI). Annals of Oncology. 76-76. 1998
- TRANSIENT GLOBAL AMNESIA FOLLOWING INTRAVENOUS HEPARIN BOLUS THERAPY IS CAUSED BY HEPARIN-INDUCED THROMBOCYTOPENIA. Thrombosis and Haemostasis. 911-911. 1993
-
journal articles
- Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial. EClinicalMedicine. 79:102991. 2025
- Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.. Neuro-Oncology. 26:1670-1682. 2024
- Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification. Modern Pathology. 35:1974-1982. 2022
- Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors. Genes. 13:2075-2075. 2022
- Germline BRCA mutations are associated with an increased likelihood of secondary cytoreductive surgery in ovarian cancer patients (116). Gynecologic Oncology. 166:S75-S76. 2022
- Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. Current Oncology. 29:231-242. 2022
- Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. Investigational New Drugs. 39:1587-1597. 2021
- The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. Clinical Pharmacokinetics. 60:921-930. 2021
- Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology. 162:103336-103336. 2021
- Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment. Cell Metabolism. 33:1205-1220.e5. 2021
- Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology. 162:103324-103324. 2021
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology. 32:757-765. 2021
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 22:620-631. 2021
- A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre. Gynecologic Oncology. 161:236-243. 2021
- Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open. 6:100043-100043. 2021
- An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. Current Oncology. 28:1114-1124. 2021
- Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C. Cells. 9:2408-2408. 2020
- Bullous vesicant-type reaction to docetaxel along the venous tract: A case report. Gynecologic Oncology Case Reports. 34:100640-100640. 2020
- Abstract PO-016: Evaluating the impact of COVID-19 on medical oncology workforce and cancer care in Canada: A serial survey study. Clinical Cancer Research. 26:po-016-po-016. 2020
- Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research. 26:2477-2486. 2020
- Impact of COVID-19 on Canadian Medical Oncologists and Cancer Care: Canadian Association of Medical Oncologists Survey Report. Current Oncology. 27:71-74. 2020
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical Cancer Research. 26:1009-1016. 2020
- Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer. 146:439-448. 2020
- Cervicomedullary hemangioblastoma treated with bevacizumab. NOA. 2:vdaa076. 2020
- Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221. Clinical Cancer Research. 25:6052-6060. 2019
- FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Annals of Oncology. 30:v403-v403. 2019
- A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. Clinica Chimica Acta. 495:355-357. 2019
- Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520. Targeted Oncology. 14:67-74. 2019
- Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. Targeted Oncology. 14:43-55. 2019
- Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model. Cancer immunology research. 6:1174-1185. 2018
- Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology. 29:viii340-viii340. 2018
- Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Journal of Medical Genetics. 55:571-577. 2018
- Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma. JAMA Oncology. 4:e173776-e173776. 2018
- Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic Oncology. 149:275-282. 2018
- Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunology, Immunotherapy. 67:575-587. 2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. Journal of the American Medical Association (JAMA). 318:2306-2306. 2017
- Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. The Lancet Oncology. 18:e709-e710. 2017
- NCOG-05. TIME TO FUNCTIONAL AND COGNITIVE DECLINE IN A PHASE 3 TRIAL OF TUMOR TREATING FIELDS WITH TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 19:vi138-vi138. 2017
- Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. Annals of Oncology. 28:viii30-viii35. 2017
- A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted Oncology. 12:655-661. 2017
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet Oncology. 18:1373-1385. 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 18:1274-1284. 2017
- Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 35:397-397. 2017
- First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 35:324-333. 2017
- Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Annals of Oncology. 28:702-710. 2017
- Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine. 376:1027-1037. 2017
- Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. Journal of Clinical Oncology. 34:4345-4353. 2016
- ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 18:vi17-vi18. 2016
- A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. Journal of Clinical Oncology. 34:LBA2-LBA2. 2016
- Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 387:1066-1074. 2016
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34:104-111. 2016
- Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer. Trials in Vaccinology. 2:e00059-e00059. 2016
- ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology. 17:v12-v13. 2015
- A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecologic Oncology. 138:55-61. 2015
- Systemic Therapy for Recurrent, Persistent, or Metastatic Cervical Cancer: A Clinical Practice Guideline. Current Oncology. 22:211-219. 2015
- A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology. 137:216-222. 2015
- Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Annals of Oncology. 26:ii3-ii3. 2015
- Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-Oncology. 17:430-439. 2015
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet Oncology. 16:87-97. 2015
- A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. British Journal of Cancer. 111:2262-2267. 2014
- A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32:1226-1235. 2014
- A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia. Annals of Oncology. 25:iv324-iv324. 2014
- A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecologic Oncology. 134:274-280. 2014
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32:243-249. 2014
- Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Review of Anticancer Therapy. 14:319-332. 2014
- Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. European Journal of Human Genetics. 22:391-395. 2014
- Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study. OncoTargets and Therapy. 7:485-485. 2014
- Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.. Molecular Cancer Therapeutics. 12:B181-B181. 2013
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs. 31:1182-1191. 2013
- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). British Journal of Cancer. 109:943-949. 2013
- A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.. Journal of Clinical Oncology. 31:5517-5517. 2013
- Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.. Journal of Clinical Oncology. 31:e13502-e13502. 2013
- Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).. Journal of Clinical Oncology. 31:2534-2534. 2013
- Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program.. Journal of Clinical Oncology. 31:11016-11016. 2013
- Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. International Journal of Cancer. 132:1547-1555. 2013
- Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. OncoTargets and Therapy. 6:107-107. 2013
- Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. OncoTargets and Therapy. 6:427-427. 2013
- A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer. Clinical Ovarian and other Gynecologic Cancer. 5:53-59. 2012
- Editorial comment on Leung et al.: CUB and zona pellucida-like domain-containing protein 1 (CUZD1): A novel serological biomarker for ovarian cancer. Clinical Biochemistry. 45:1547-1547. 2012
- First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Annals of Oncology. 23:2613-2619. 2012
- A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia.. Journal of Clinical Oncology. 30:5019-5019. 2012
- Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology. 30:5001-5001. 2012
- A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecologic Oncology. 125:136-140. 2012
- Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Oncology. 13:154-162. 2012
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Annals of Oncology. 23:238-244. 2012
- Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Current Oncology. 18:303. 2011
- Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective (vol 18, S20, 2011). Current Oncology. 18:303-303. 2011
- Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology. 18:303-303. 2011
- Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer. 105:1144-1150. 2011
- Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Current Oncology. 18:S20-S27. 2011
- 6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas. European Journal of Cancer. 47:S473-S473. 2011
- Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. British Journal of Cancer. 105:884-889. 2011
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncology. 12:852-861. 2011
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17:1582-1590. 2011
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 104:756-762. 2011
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of Oncology. 22:335-340. 2011
- A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecologic Oncology. 118:308-312. 2010
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. European Journal of Cancer. 46:1573-1579. 2010
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 20:787-793. 2010
- A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia.. Journal of Clinical Oncology. 28:5038-5038. 2010
- Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?. Clinical Cancer Research. 16:1341-1341. 2010
- Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. Clinical Biochemistry. 42:1162-1165. 2009
- Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. Journal of Clinical Oncology. 27:3097-3103. 2009
- Novel developments in angiogenesis cancer therapy. Current Oncology. 16:191-195. 2009
- A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Journal of Clinical Oncology. 27:5563-5563. 2009
- A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium. Journal of Clinical Oncology. 27:5591-5591. 2009
- A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 27:5576-5576. 2009
- A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 27:5559-5559. 2009
- Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). Clinical Cancer Research. 27:3528-3528. 2009
- Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. Journal of Clinical Oncology. 27:3558-3558. 2009
- Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. Journal of Clinical Oncology. 27:5577-5577. 2009
- Novel Developments in Angiogenesis Cancer Therapy. Current Oncology. 16:50-54. 2009
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab. Clinical Cancer Research. 14:7554-7563. 2008
- Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones. Journal of Clinical Oncology. 26:3301-3302. 2008
- Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy. Journal of Thoracic Oncology. 3:716-722. 2008
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14:3450-3455. 2008
- Cytokine elevations in acute coronary syndrome and ovarian cancer: A mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. Clinical Biochemistry. 41:607-610. 2008
- Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. Journal of Clinical Oncology. 26:1324-1330. 2008
- A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research. 14:833-839. 2008
- A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Investigational New Drugs. 25:553-558. 2007
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer. Current Oncology. 14:195-208. 2007
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13:4849-4857. 2007
- UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. Gynecologic Oncology. 106:305-310. 2007
- CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib—A trial of the PMH Phase II Consortium. Journal of Clinical Oncology. 25:5519-5519. 2007
- Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs). Journal of Clinical Oncology. 25:6601-6601. 2007
- Ontario Cervical Cancer Screening Clinical Practice Guidelines. Journal of Obstetrics and Gynaecology Canada. 29:344-353. 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. Oncologist. 12:426-437. 2007
- Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer. Cancer. 109:692-702. 2007
- An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13:977-985. 2007
- Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. International Journal of Gynecological Cancer. 17:1194-1204. 2007
- Outcomes for systemic therapy in women with ovarian cancer. Gynecologic Oncology. 103:554-558. 2006
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of Clinical Oncology. 24:4699-4707. 2006
- A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecologic Oncology. 102:300-308. 2006
- Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. International Journal of Gynecological Cancer. 16:1536-1544. 2006
- Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. International Journal of Gynecological Cancer. 16:1536-1544. 2006
- Angiogenesis pathway gene polymorphisms associated with clinical outcome in recurrent ovarian cancer treated with low dose cyclophosphamide and bevacizumab: A California Consortium Trial. Journal of Clinical Oncology. 24:5017-5017. 2006
- Dose banding of chemotherapy doses at the Juravinski Cancer Centre. Journal of Clinical Oncology. 24:6099-6099. 2006
- Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. Journal of Clinical Oncology. 24:5084-5084. 2006
- Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination. Clinical Cancer Research. 12:2141-2149. 2006
- Immuno-Isolation in Cancer Gene Therapy. Current Gene Therapy. 6:181-191. 2006
- Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor). Journal of Clinical Oncology. 24:1195-1203. 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?. European Journal of Cancer. 42:548-556. 2006
- Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of Oncology. 17:334-340. 2006
- First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival. International Journal of Gynecological Cancer. 15:221-221. 2005
- An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Investigational New Drugs. 23:437-443. 2005
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology. 16:1688-1694. 2005
- Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer. Journal of Clinical Oncology. 23:5597-5604. 2005
- A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial. Journal of Clinical Oncology. 23:3127-3127. 2005
- A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium. Journal of Clinical Oncology. 23:4166-4166. 2005
- Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. Journal of Clinical Oncology. 23:5000-5000. 2005
- A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer☆. Urologic Oncology: Seminars and Original Investigations. 23:143-149. 2005
- A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 23:147-155. 2005
- A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23:165-170. 2005
- An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Investigational New Drugs. 23:63-71. 2005
- 393 A phase II study of OSI-774 given in combination with carboplatin in patients with recurrent ovarian cancer (NCIC IND.149). European Journal of Cancer, Supplement. 2:118-118. 2004
- A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational New Drugs. 22:263-275. 2004
- Screening Postmenopausal Women for Ovarian Cancer: A Systematic Review. Journal of Obstetrics and Gynaecology Canada. 26:717-728. 2004
- A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Journal of Clinical Oncology. 22:5054-5054. 2004
- A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Journal of Clinical Oncology. 22:5054-5054. 2004
- Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Journal of Clinical Oncology. 22:5005-5005. 2004
- Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Journal of Clinical Oncology. 22:5005-5005. 2004
- FIBRINOLYTIC FACTORS AND FIBRINOGEN DEGRADATION PRODUCTS (FDPS) IN HUMAN OVARIAN CANCER ASCITES: FDPS CONTRIBUTE TO THE NET ANTI-ANGIOGENIC POTENTIAL OF ASCITES. Cardiovascular Pathology. 13:174-175. 2004
- A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Annals of Oncology. 15:665-670. 2004
- 159 Phase II study of OSI-774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC ctg Ind.149. European Journal of Cancer, Supplement. 1:S51-S51. 2003
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.. Clinical Cancer Research. 9:2457-2464. 2003
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies. Current Pharmaceutical Design. 8:2249-2253. 2002
- Malignant Ascites Fluid (MAF), Including Ovarian-Cancer-Associated MAF, Contains Angiostatin and Other Factor(s) Which Inhibit Angiogenesis. Gynecologic Oncology. 86:279-287. 2002
- Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer–a Meta-analysis. Clinical Oncology. 14:203-212. 2002
- Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.. Cancer Research. 62:1588-1591. 2002
- A Comparison of Two Prophylactic Regimens for Hypersensitivity Reactions to Paclitaxel. Gynecologic Oncology. 84:420-425. 2002
- A Phase II Trial of JM-216 in Cervical Cancer: An NCIC CTG Study. Gynecologic Oncology. 84:327-331. 2002
- Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Current Opinion in Obstetrics and Gynecology. 14:67-73. 2002
- Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 23:104-110. 2002
- Hypercalcemia of Malignancy. American Journal of Cancer. 1:179-187. 2002
- NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer. European Journal of Cancer. 37:S289-S289. 2001
- Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. International Journal of Cancer. 91:857-862. 2001
- A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Annals of Oncology. 11:1579-1584. 2000
- Novel strategies for systemic treatment of endometrial cancer. Expert Opinion on Investigational Drugs. 9:2831-2853. 2000
- Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. International Journal of Gynecological Cancer. 10:463-468. 2000
- Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells. Molecular and Cellular Biology. 20:3764-3771. 2000
- Ascites fluid induces epithelial proliferation and increases vascular permeability in the chorioallantoic membrane. Prostaglandins and Other Lipid Mediators. 59:175-175. 1999
- NCIC CTG IND102: a phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix. European Journal of Cancer. 35:S235-S235. 1999
- Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab. Current Oncology. 6:131-137. 1999
- Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies. Current Oncology. 6:74-77. 1999
- Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.. Clinical and Experimental Metastasis. 17:33-42. 1999
- Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies. Current Oncology. 5:181-187. 1998
- Bone metastases: A review of their pathogenesis. Current Oncology. 5:114-118. 1998
- Decidua-Associated Suppressor Cells in Abortion-Prone DBA/2-Mated CBA/J Mice that Release Bioactive Transforming Growth Factor β2-related Immunosuppressive Molecules Express a Bone Marrow-Derived Natural Suppressor Cell Marker and γδ8 T-Cell Receptor1. Biology of Reproduction. 56:1351-1360. 1997
- A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma. Gynecologic Oncology. 64:80-87. 1997
- Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.. Invasion and Metastasis. 17:312-322. 1997
- A Subset of Patients With Recurrent Spontaneous Abortion Is Deficient in Transforming Growth Factor β‐2‐Producing “Suppressor Cells” in Uterine Tissue Near the Placental Attachment Site. American Journal of Reproductive Immunology. 34:52-64. 1995
- Telomerase activity associated with acquisition of malignancy in human colorectal cancer.. Cancer Research. 55:2533-2536. 1995
- Characterization of murine pregnancy decidua transforming growth factor beta. I. Transforming growth factor beta 2-like molecules of unusual molecular size released in bioactive form. Biology of Reproduction. 52:1380-1388. 1995
- CD56+ lymphoid cells in human first trimester pregnancy decidua as a source of novel transforming growth factor-β2-related immunosuppressive factors. Human Reproduction. 10:976-976. 1995
- Erratum: A subset of patients with recurrent spontaneous abortion is deficient in transforming growth factor β-2-producing 'Suppressor' cells in uterine tissue near the placental attachment site (American Journal of Reproductive Immunology (1995) 34 (53-64)). American Journal of Reproductive Immunology. 34:208. 1995
- Immunology: CD56+ lymphoid cells in human first trimester pregnancy decidua as a source of novel transforming growth factor-β2-related immunosuppressive factors. Human Reproduction. 9:2270-2277. 1994
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8:1817-1824. 1994
- Transient global amnesia associated with acute heparin-induced thrombocytopenia. American Journal of Medicine. 97:489-491. 1994
- Establishment and characterization of four human epithelial ovarian carcinoma cell lines. Cancer. 74:900-906. 1994
- Telomerase activity in human ovarian carcinoma.. Proceedings of the National Academy of Sciences of the United States of America. 91:2900-2904. 1994
- Telomerase, Cell Immortality, and Cancer. Cold Spring Harbor Symposia on Quantitative Biology. 59:307-315. 1994
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8 Suppl 3:S42-S49. 1994
- A NOVEL TRANSFORMING GROWTH FACTOR IS PRESENT IN MALIGNANT ASCITES FROM HUMAN OVARIAN CARCINOMA. Journal of immunotherapy (Hagerstown, Md. : 1997). 14:359-359. 1993
- Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma. Journal of the National Cancer Institute. 85:823-825. 1993
- TRANSFORMING GROWTH FACTOR-BETA IS PRESENT IN ACTIVE FORM IN ASCITIC FLUID FROM HUMAN OVARIAN CARCINOMA. Journal of immunotherapy (Hagerstown, Md. : 1997). 13:61-61. 1993
- A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. International Journal of Gynecology and Obstetrics. 39:359-360. 1992
- Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cellular Immunology. 142:207-216. 1992
- A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecologic Oncology. 44:223-226. 1992
- Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor. Journal of the National Cancer Institute. 83:1748-1753. 1991
- Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor. Cancer Immunology, Immunotherapy. 32:296-302. 1991
- Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targets. Cellular Immunology. 136:122-132. 1991
- A phase I study of GM-CSF, cyclophosphamide (CP), and escalating doses of carboplatin (CBDCA) in chemotherapy-Naïve patients with ovarian cancer. Gynecologic Oncology. 40:169-170. 1991
- Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. British Journal of Cancer. 58:415-418. 1988
- Imaging Studies and the Prognostic Value of Serum Calcitonin in Staging Small-Cell Lung Cancer. Tumor Biology. 8:211-217. 1987
- ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXIC REACTION .1. MORPHOLOGICAL AND FUNCTIONAL-HETEROGENEITY OF THE RABBIT CYTOTOXIC-CELLS. Immunology. 38:665-676. 1979
- ASSESSING THE FREQUENCY OF CA-125 MEASUREMENTS WITHIN HAMILTON HEALTH SCIENCES AND ST. JOSEPH’S HEALTHCARE. Clinical and Investigative Medicine. 32:6-6.
- Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. Current Oncology. 18:303-303.
- Study Design Solutions for Adjuvant and Maintenance Therapy in Cancer: Ovarian Cancer as an Example. SN Comprehensive Clinical Medicine. 4:186.